Oseltamivir

Generic Name: Oseltamivir

Brand Names: Ebilfumin, Tamiflu

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₈N_₂O_₄

CAS Number: 196618-13-0

Unique Ingredient Identifier: 20O93L6F9H

Background: Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...

Indication: According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...

Associated Conditions: Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B

Associated Therapies: -

Clinical Trials

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

Phase 4

Completed

Conditions: Influenza

Interventions: Drug: Oseltamivir
Drug: Peramivir

First Posted Date: 2015-11-20

Last Posted Date: 2019-10-04

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 180

Registration Number: NCT02609399

Locations: 🇺🇸
Maricopa Integrated Health System, Phoenix, Arizona, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: Oseltamivir
Drug: MEDI8852
Drug: Placebo

First Posted Date: 2015-11-13

Last Posted Date: 2018-06-08

Lead Sponsor: MedImmune LLC

Target Recruit Count: 126

Registration Number: NCT02603952

Locations: 🇿🇦
Research Site, Welkom, South Africa

A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza

Phase 4

Terminated

Conditions: Influenza

Interventions: Other: Placebo
Drug: Oseltamivir

First Posted Date: 2015-09-25

Last Posted Date: 2017-08-04

Lead Sponsor: McMaster University

Target Recruit Count: 1

Registration Number: NCT02561169

Locations: 🇨🇦
Foothills Medical Centre Emergency Department, Calgary, Alberta, Canada

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Phase 2

Completed

Conditions: Influenza A Virus

Interventions: Drug: Placebo
Drug: JNJ-63623872
Drug: Oseltamivir

First Posted Date: 2015-08-25

Last Posted Date: 2020-03-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 102

Registration Number: NCT02532283

A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Oseltamivir
Drug: Tamiflu®

First Posted Date: 2015-07-24

Last Posted Date: 2015-07-24

Lead Sponsor: Genuine Research Center, Egypt

Target Recruit Count: 24

Registration Number: NCT02507648

Locations: 🇪🇬
Genuine Research Center GRC, Cairo, Egypt

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Phase 3

Completed

Conditions: Influenza

Interventions: Drug: Peramivir
Drug: Oseltamivir

First Posted Date: 2015-02-23

Last Posted Date: 2021-03-23

Lead Sponsor: BioCryst Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT02369159

Locations: 🇿🇦
Peramivir Investigative Site, Pretoria, South Africa
🇺🇸
Peramivir investigative site, South Jordan, Utah, United States

A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection

Phase 2

Completed

Conditions: Influenza

Interventions: Drug: MHAA4549A
Drug: Placebo
Drug: Oseltamivir

First Posted Date: 2014-11-18

Last Posted Date: 2018-06-18

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 168

Registration Number: NCT02293863

Locations: 🇲🇽
CEPREP; Hospital Universitario, Monterrey, Mexico
🇵🇱
Oddział Anestezjologii i Intensywnej Terapii Wojewódzki Specjalistyczny Szpital im dr Wł Biegańsk, Łódź, Poland
🇧🇬
MHAT "Dr. Tota Venkova"- Gabrovo, Gabrovo, Bulgaria

and more 168 locations

An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.

Phase 4

Withdrawn

Conditions: Pulmonary Disease
Influenza

Interventions: Drug: oseltamivir
Other: Placebo

First Posted Date: 2014-11-04

Last Posted Date: 2018-10-26

Lead Sponsor: McMaster University

Registration Number: NCT02282384

A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Drug: VX-787
Drug: Oseltamivir

First Posted Date: 2014-10-13

Last Posted Date: 2014-11-04

Lead Sponsor: Janssen Infectious Diseases BVBA

Target Recruit Count: 38

Registration Number: NCT02262715

Treatment of Severe Influenza A Infection

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Drug: Celecoxib
Drug: Oseltamivir
Drug: Placebo

First Posted Date: 2014-04-09

Last Posted Date: 2019-10-21

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 107

Registration Number: NCT02108366

Locations: 🇭🇰
Ivan Hung, Hong Kong, Hong Kong

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy